scholarly journals Assessment of Lung Function Before and After Allogeneic Hematopoietic Stem Cell Transplantation in a Single Pediatric Center

2009 ◽  
Vol 15 (2) ◽  
pp. 82
Author(s):  
T.C. Quigg ◽  
Y.-J. Kim ◽  
W.S. Goebel ◽  
C.B. Spiegel ◽  
P.R. Haut
Keyword(s):  
Stem Cell ◽  
Lung Function ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Before And After ◽  
Pediatric Center

Comparison of Lung Function after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5105-5105
Author(s):  
Jason W. Chien ◽  
Michael B. Maris ◽  
Tanyalak Parimon ◽  
Brenda M. Sandmaier ◽  
David G. Maloney ◽  
...  
Keyword(s):  
Stem Cell ◽  
Lung Function ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Lung Function Decline ◽  
Hematopoietic Stem ◽  
Before And After ◽  
One Year

Abstract Lung function decline is a well-recognized occurrence after myeloablative hematopoietic stem cell transplantation (HCT) that has not been studied after nonmyeloablative conditioning regimens. We examined the lung function of patients before and after receiving nonmyeloablative and myeloablative preparative regimens. Before HCT, nonmyeloablative patients had lower baseline values of percent of predicted FEV1 (pFEV1) and FVC (pFVC), reflecting their greater ages and often, poorer, medical conditions. However, nonmyeloablative patients experienced a slower overall rate of pFEV1 decline after HCT (4% ± 17 versus 12.7% ± 32 per year, P = 0.001), with patients >50 years of age having the lowest risk for rapid pFEV1 decline in a multivariable model. Rapid pFEV1 decline was associated with both total body irradiation (TBI) and non-TBI based myeloablative regimens. These findings were evident even one year or more after HCT. Myeloablative patients had a higher risk for death based upon pretransplant pFEV1 (HR 7.2 versus 3.9), with a 2-year survival rate of 0% among myeloablative patients with a pretransplant pFEV1 <60% (30% among nonmyeloablative patients). These results suggested that despite having worse lung function, patients receiving the nonmyeloablative regimen might experience less pulmonary toxicity and had a lower risk of mortality associated with abnormal pretransplant lung function.

Sign in / Sign up

Export Citation Format

Share Document